Merck no-go decision spells the end for JT's novel osteoporosis drug
This article was originally published in Scrip
Executive Summary
Merck & Co's decision to end a licensing deal with Japan Tobacco (JT) for a novel therapy for post-menopausal osteoporosis has also prompted the Japanese firm to discontinue its development programme for the oral calcium-sensing receptor antagonist.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Catchup Capsule: Key APAC Insights You Need To Read
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Catchup Capsule: Key APAC Insights You Need To Read
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Need a specific report? 1000+ reports available
Buy Reports